^
Association details:
| Biomarker: | CCNE1 amplification |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | volasertib (NBL-001) (PLK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combinatorial inhibition of Polo-like kinase 1 (PLK1) and microtubule dynamics to induce synthetic lethality in ovarian cancer cells with CCNE1-amplification
Published date:
05/16/2018
Excerpt:
Following the treatment of paclitaxel with BI6727, we observed synergistic effects on cell vitality of CCNE1-amplified ovarian cells, resulting in apoptosis. The combination of paclitaxel with PLK1-inhibitors is a promising novel strategy for the treatment of HGSOC patients with CCNE1-amplification.
Secondary therapy:
paclitaxel
DOI:
10.1200/JCO.2018.36.15_suppl.e17537
